CLVS goodness...massive blood today...look at monthly....amazing...guess everyone thinks a massive pipeline of cancer treating drugs costing $400 million per year to develop with revenues of $160 million and growing with one FDA approved drug from 2020 Rubraca is unsustainable...and a CEO that has built and sold for $ here and doing it again imo. $200,000,000 shelf going into 2021 with plenty $ in bank.
Bring me the $5.50's tomorrow you hostile takeover drive the share price down takeover artisians.
Hey!, let's take the scenic route artists! So, I can keep adding into the $2's.
NO PRESSURE...NO DIAMONDS...
glta.
News 
Market Data 
Discover 
